ABSTRACT Background: Parenteral nutrition (PN) is the main treatment for intestinal failure. Objective: We aimed to review the indications for home parenteral nutrition (HPN) in children and describe the outcome over a 14-y period from a single center. Design: We conducted a retrospective study that included all children who were referred to our institution and discharged while receiving HPN between 1 January 2000 and 31 December 2013. The indications for HPN were divided into primary digestive diseases (PDDs) and primary nondigestive diseases (PNDDs). We compared our results to a previous study that was performed in our unit from 1980 to 2000 and included 302 patients. Results: A total of 251 patients were included: 217 (86%) had a PDD. The mean 6 SD age at HPN onset was 0.7 6 0.3 y, with a mean duration of 1.9 6 0.4 y. The indications for HPN were short bowel syndrome (SBS) (59%), PNDD (14%), congenital enteropathies (10%), chronic intestinal pseudo-obstruction syndromes (9%), inflammatory bowel diseases (5%), and other digestive diseases (3%). By 31 December 2013, 52% of children were weaned off of HPN, 9% of the PDD subgroup had intestinal transplantation, and 10% died mostly because of immune deficiency. The major complications of HPN were catheter-related bloodstream infections (CRBSIs) (1.7/1000 d of PN) and intestinal failure-associated liver disease (IFALD) (51 children; 20% of cohort). An increased rate of CRBSIs was observed compared with our previous study, but we saw a decreasing trend since 2012. No noteworthy deceleration of growth was observed in SBS children 6 mo after weaning off HPN. Conclusions: SBS was the major indication for HPN in our cohort. IFALD and CRBSIs were potentially life-threatening problems. Nevertheless, complication rates were low, and deaths resulted mostly from the underlying disease.
INTRODUCTION
Intestinal failure (IF) 7 is defined as a critical reduction of functional gut mass below the minimum needed for adequate growth in children and weight maintenance in adults (1) (2) (3) (4) (5) . This condition requires parenteral nutrition (PN) as long as the intestinal function is insufficient. In developed countries, primary digestive diseases (PDDs) responsible for IF fall into 3 groups: short bowel syndrome (SBS) [including long-segment Hirschsprung disease], congenital enteropathies (CEs) caused by genetic defects in the enterocytes, and chronic intestinal pseudoobstruction syndrome (CIPOS) (1) .
Whatever the cause of IF, long-term PN is the mainstay of therapy (2, 5) . Children with primary nondigestive diseases (PNDDs) such as immune deficiencies (IDs) can also benefit from PN (6) . Home PN (HPN) allows children to grow in their familial environment (2, 4, 7, 8) . In France in 2014, the number of patients aged ,18 y and receiving HPN was 262 for 65 million inhabitants, with an incidence of w50 new cases/y (3, 5) . Our institution has the largest pediatric HPN program in Europe (6) .
The survival of children on long-term PN increased dramatically during the past 3 decades (1, 3, 5, 6) . Nevertheless, complications such as catheter-related bloodstream infections (CRBSIs), intestinal failure-associated liver disease (IFALD), and loss of venous access can challenge the prognosis (1, 5, 9) . Liver failure is the major life-threatening complication and is an indication of combined liver and small bowel transplantation (L-SBTx) (10, 11) .
A multidisciplinary team, appropriate handling of central venous catheters (CVCs), and tailored HPN are crucial determinants of prognosis (1, 10) . Intestinal transplantation (ITx) is indicated only in patients with irreversible IF who develop life-threatening complications (2) . An early referral to an IF expert center is mandatory for a case-by-case treatment strategy (12, 13) .
The aim of this study was to review the indications and outcomes of pediatric HPN over a 14-y period in a large cohort managed in a single certified French center.
METHODS

Criteria for inclusion
According to the French Regional Health Agency, our hospital is the single certified HPN "expert" center for children. Six other hospitals are certified for managing HPN in pediatric patients in France. All patients requiring HPN must be referred to one of these centers to be supported by social security. Children were eligible for HPN when they received PN for .3 mo while in stable condition and with the prospect of long-term PN dependency.
Patients' referral and geographic origin
All children discharged while receiving HPN between 1 January 2000 and 31 December 2013 were included. They were referred by our institution, hospitals in the Ile-de-France (IDF) area (Paris and surrounding suburbs), and hospitals outside IDF. For hospitals outside IDF, the follow-up included a routine evaluation in our hospital's outpatient clinics, whereas emergent situations were mostly managed by the local hospital of origin.
Definition of PDD and PNDD subgroups
PDDs were defined as IF caused by SBS, CE, CIPOS, and inflammatory bowel disease (IBD). The SBS included intestinal atresia, midgut volvulus, necrotizing enterocolitis, gastroschisis, long-segment Hirschsprung disease, and other causes of PDD. The remnant bowel was measured at the time of surgery along the antimesenteric border from the Treitz ligament. Congenital enteropathies included microvillus inclusion disease, congenital tufting enteropathy, trichohepatoenteric syndrome, and others. PNDD included patients with a variety of disorders that impaired digestive functions and intestinal autonomy (e.g., ID and metabolic disorders).
Vascular access and handling
All children had a CVC Broviac-type or arteriovenous fistula. They were all inserted under general anesthesia in the superior vena cava after a vascular ultrasound. In 2007, we started using mild soap and hydroalcoholic solutions for handwashing. We also switched to mechanical valve needleless connectors on the CVC to avoid needle stick injuries, better visualize the internal structure, and reduce the use of prophylactic thrombolytic agents. After weaning off PN, the CVC was kept for 3-6 mo.
PN intake
The PN formula was prepared by Fasonut-Baxter and delivered weekly to the children's homes with the use of a specialized transportation along with the infusion materials. It was customized for each child with the use of a compartment bag for glucose, amino acids, electrolytes, minerals, vitamins, and trace elements and another for intravenous lipid emulsion. The amino acids were Vintène (Baxter) for children aged .10 y and Vaminolact (Fresenius Kabi) or Primène (Baxter) for children aged #10 y. The nonprotein energy intake (NPEI) included the energy provided by glucose and lipids in the PN. The optimal 
Enteral feeding
Patients requiring long-term PN for SBS were preferentially orally fed to promote intestinal adaptation. Enteral tube feeding (ETF) was used in 2 situations: in children with eating disorders and for some children during the process of PN weaning by replacing 1 night of PN infusion by ETF. The latter was administered by a nasogastric tube or gastrostomy and with the use of extensively hydrolyzed formulas. Congenital enteropathies and CIPOS did not receive ETF.
PN training, discharge, and follow-up
The parents were trained in our institution by specialist nurses for 2-3 wk. A home nursing service supported by social security can be available daily for parents who cannot or do not wish to provide care. Once discharged from the hospital, parents were accompanied home by an HPN nurse and could call our division 24 h. Whenever a child in our HPN program was admitted to another hospital, we were contacted and updated regularly about his or her health condition, and a medical report was sent to us at discharge. Follow-up was performed in a specific multidisciplinary outpatient clinic by a gastroenterologist, pharmacist, dietitian, and HPN nurse 4 times/y or more if needed. The composition and volume of the PN solution were adapted to the child's requirements and growth. Assessment included a blood exam [cell blood count, electrolytes, calcium, phosphorus, magnesium, iron, and liver function tests and, once a year, vitamins A, E, and 25-hydroxyvitamin D], insulin-like growth factor-1, parathyroid hormone, trace elements, and lipid profiles. The drawing was done from either the CVC or the peripheral vein according to age and/or easiness for the child. A urinary analysis was performed for electrolytes, calcium, and phosphorus. The number of HPN weekly infusions and calories were slowly decreased and adjusted to the oral feeding of the child, taking into account the remaining bowel length in SBS children. The resting energy expenditure (REE) was calculated with the use of Schofield formulas (14) . We routinely used the ratio NPEI from PN to REE to reflect the level of PN dependency rather than the isolated enteral calories, which might be impeded by intestinal reduced absorption. Herein we considered the last values available in our files at the end of the study. The PN was stopped when the calories were decreased to ,20% of REE.
Data collection and analysis
The collection of data included demographics, indication for HPN, length of remnant small bowel, presence of ileocecal valve (ICV), liver function tests (LFTs), liver biopsy if available, complications related to CVC (infection, thrombosis, tearing), CVC replacements, date and cause of HPN discontinuation, and growth of children with SBS. The data were collected on 31 December 2013 or on the date of HPN discontinuation.
Definition of outcome and prognosis factors
Outcome was defined as the status of the patient at the end of the study period: PN weaning, ITx, or death. These data were studied according to the indication for HPN and the occurrence of IFALD and CRBSI. The indications for ITx were end-stage liver disease, extensive vascular thrombosis, repeated life-threatening CRBSI and dehydration episodes. A multidisciplinary group of gastroenterologists, hepatologists, surgeons, and anesthesiologists decided upon ITx (either isolated ITx or L-SBTx) after collective discussions. The child was registered on the French Biomedicine Agency list as extremely urgent, critical, or stable according to his or her health condition. The reported mortality rates corresponded to patients who died while still receiving HPN.
Catheter-related complications
CRBSI was defined as a fever of .388C with $2 blood samples growing for the same pathogen (1 sample from the CVC and the other from the peripheral vein or 2 samples from the CVC) with no other infection site. Children were divided into 2 subcategories: history of at least 1 CRBSI (.1 CRBSI) or no history of CRBSI. The diagnosis of tunnelitis was clinical with local signs of infection along the CVC subcutaneous pathway. The CVC was removed only in case of fungal infection, tunnelitis, secondary infection (endocarditis, osteitis, or arthritis), resistance to antibiotics, or failure of repairing a ruptured CVC. Since October 2011, we used Taurolidine-citrate locks (TauroLock) for children who had $2 CRBSIs over a 12-mo period. When parents were unable to infuse through CVC, a catheter thrombosis was suspected. The child was urgently hospitalized, and an Actosolv lock (Urokinase) was administrated according to the unit protocol. A vascular ultrasound was also performed. A blood coagulation workup was done when a child had .2 episodes of thrombosis.
Assessment of liver disease
The definition of IFALD was based on an abnormal LFT (transaminases, bilirubin, or g-glutamyl-transpeptidase) .1.5 times the upper limit of normal. A liver biopsy was performed when abnormal LFTs persisted for .6 mo and the screening for hepatotropic virus was negative. The METAVIR classification was used to assess the severity of liver disease (17) . 
OUTCOME OF HOME PARENTERAL NUTRITION IN CHILDREN
Growth of children with SBS
We studied the growth of children with SBS because they did not receive corticosteroids, unlike other subgroups. The effect on growth of iatrogenic elements other than HPN was absent or minimal. Children were weighed with the use of a digital scale accurate to 0.1 kg. The height was measured in a recumbent position to the nearest 0.1 cm (length) for children aged ,2 y. All weight and height values were reported to the French growth charts established by Sempé and Pédron (15, 16) .
Statistical analyses
Statistical analyses were performed with the use of R statistical software version 3.0.2, SPSS version 20.0 (SAS), and Microsoft Office Excel 2010. Results of means were accompanied by 95% CIs. Student's t and chi-square tests were used to compare means and rates, respectively. Quantitative variables were expressed as means 6 SDs. Factors associated to weaning off HPN, ITx, and death were studied with the use of univariate analyses. The a-risk threshold was set at P = 0.05.
RESULTS
HPN incidence and demographic data
Of the 251 children in the study, 137 (55%) were boys. The incidence of new patients per year was 18 6 4 (range: [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . The children in the first 7-y study period were referred mainly from the IDF area. Later, the number of children coming from outside IDF increased ( Figure 1) . The mean age at HPN onset was 0.7 6 0.3 y (0.6 y for PDD and 1.3 y for PNDD).
Indications for HPN
The largest PDD subgroup included 148 children with SBS (59%) ( Table 1 ). The mean length of remnant small bowel was 50 6 14 cm (range: 2-90 cm), and the ICV was present in 76 patients (51%). Four children had SBS secondary to bowel ischemia-3 after intussusception on Meckel diverticulum and 1 panarteritis nodosa. Of the 25 children with congenital enteropathies, 5 remained without a specific diagnosis (20%). Rare causes of PDD (n = 8; 3%) included chylous ascitis (n = 3), intestinal lymphangectasia with severe protein-losing enteropathy (n = 4), and Bannayan-Riley-Ruvalcaba syndrome (total intestinal polyposis, n = 1). Thirty-four children had a PNDD (14%) mostly because of ID (n = 25; 74%). Of these, 1 child with an IL-10 receptor deficiency underwent bone marrow transplantation and was weaned off PN. The age distribution at HPN onset is shown in Table 2 .
Outcome and prognosis factors
On 31 December 2013, 131 children (52%) of the entire cohort were weaned off PN after 1.9 6 0.4 y. Eighty-seven children (34%) were still receiving HPN, 12 of whom were referred to an adult center. Table 3 shows factors influencing weaning off HPN, ITx, and death. The patients who were most likely weaned off HPN were those with IBD (P = 0.001) and SBS (P = 0.008). Children with SBS who were weaned off HPN (n = 91) had a bowel length of 76 6 6 cm, and 62% had intact ICV. Those who were not weaned off HPN had a bowel length of 24 6 5 cm (P = 0.001), and 35% had an ICV (P = 0.002). ITx was significantly performed mostly in patients with SBS (P = 0.04) and CE (P , 0.001). Death most likely occurred in patients with ID (P , 0.001) or another PNDD (P = 0.002) and the least in SBS patients (P , 0.001). IFALD was significantly associated with less PN weaning (P = 0.043). CRBSIs did not influence the outcome.
Complications
Hospitalizations and infections
The mean number of hospitalizations was 6.5/patient; 2.3 hospitalizations were related to CVC (35%). The mean number of days in the hospital was 25 6 2/y. During the 14-y period, 318 episodes of CVC-related infections occurred: 287 episodes of CRBSI (1.1 episode/patient) and 31 episodes of tunnelitis. CRBSI was confirmed in 24% of cases of fever. During our study period, the mean number of CRBSIs was 1.7 6 0.5/1000 d of PN. We had 2 peaks of CRBSI around 2.3/1000 d of HPN (Figure 2) . Of those children who had a CRBSI (n = 137), 34% had more than 1 episode of confirmed bacteremia ( Table 4) . Coagulase-negative staphylococci were the most frequent pathogens involved in CRBSI (Figure 3) . At the end of our study, Taurolidine-citrate locks (TauroLock) were used in 25 children with a mean followup of 1.4 6 0.4 y. In those children, CRBSIs decreased from 5.2 to 0.2/1000 d of CVC (P = 0.001).
Catheter types, replacement, and thrombosis
Of the 251 children studied, nearly all (n = 249) had a Broviactype CVC; 2 had an arteriovenous fistula. A total of 133 catheters had to be changed in 60 children (2.2/patient) after a mean of 2.3 6 0.4 y. The indications for CVC replacement were leakage or rupture (n = 60), Staphylococcus aureus (SA) or fungi in CRBSIs (n = 45), CRBSI persistent for .48 h of targeted antibiotherapy (n = 22), and CVC thrombosis with failure of Actosolv (Urokinase) lock regimen (n = 6).
IFALD and liver biopsies
Of all 251 children, 68 (27%) had abnormal LFTs. In 17, they were observed before starting HPN and were excluded from the analysis. In the other 51 children (20%), the abnormalities were seen after 2.9 6 2.3 y of HPN (median: 4.3 y). All children with abnormal LFTs for .6 mo had a liver biopsy (transjugular, n = 2; percutaneous, n = 49). Twenty-eight children had increased transaminases (55%), 12 had increased bilirubin or g-glutamyltranspeptidase (24%), and 11 had both (21%). On follow-up, LFTs improved in 27 of 51 children (53%), were stable in 16 (31%), and worsened in 8 (16%). Abnormal LFTs were seen in 21% of children with PDD (n = 46) and 15% with PNDD (n = 5). Children receiving PN for congenital enteropathies had the highest prevalence of abnormal LFTs (44%) ( Table 5) . Eighty-six liver biopsies were performed for the 51 children. The METAVIR score was F0 (no fibrosis) in 21 biopsies (24%), F1 in 20 (24%), F2 in 21 (24%), F3 in 10 (12%), and F4 (cirrhosis) in 14 (16%).
Intestinal transplantation
Nineteen children in the PDD subgroup (9%) underwent ITx (14 isolated ITx and 5 L-SBTx) after 2.8 6 0.8 y of HPN. Indications were repeated life-threatening CRBSIs (n = 10), end-stage liver disease (n = 5), extensive vascular thrombosis (n = 2), and repeated life-threatening dehydration episodes (n = 2). Within 18 mo after ITx, 95% (18 of 19) were weaned off HPN. One child was weaned off HPN after 2.5 y. In 7 children (37%), the graft was removed after a mean of 25 6 6 mo for rejection. Three children died because of uncontrollable acute rejection after ITx.
Mortality
Twenty-four children died while receiving HPN (10%). They were not included in the calculation of weaning rate and HPN duration. Six children had a PDD (3% of the subgroup) and died of ITx complications (n = 3), end-stage IFALD (n = 2), and hypovolemic shock (n = 1). The other 18 children had a PNDD (53% of the subgroup) and died of infections (ID; n = 15), metabolic disease (n = 1), cardiomyopathy (n = 1), and respiratory failure (n = 1). The longest duration of HPN in the PNDD subgroup was 7 y. The death rate was significantly higher in patients with PNDD (P , 0.001) (Figures 4 and 5) . Table 6 compares our results to the previous study performed in our unit (6) .
Growth in SBS and PN energy requirements
Ninety-one children with SBS were weaned off HPN at a mean age of 2.9 6 0.6 y. There was no significant difference in weightfor-age and height-for-age z scores at weaning off HPN and follow-up visits (P = 0.23 and 0.16, respectively). For children with SBS still receiving HPN at the end of the study period (n = 45), the level of PN dependency assessed by the NPEI:REE ratio was 1.31 6 0.2 ( Table 7) .
DISCUSSION
This study reports the long-term outcome of 251 children enrolled in a single-center French HPN program over a 14-y period. SBS is the leading indication for HPN (6, (18) (19) (20) (21) (22) . In this study, the delay to weaning off PN was 1.9 6 0.4 y, which is less than we previously reported (6) . This is probably because of better surgical techniques developed in the past 10 y and early oral feeding, which has promoted intestinal adaptation and led to a better weaning rate and shorter duration of HPN (2, 3, 23, 24) . Children with SBS in our unit were not all early fed before 2000. The current data confirm that children with SBS who were weaned off HPN had a remaining bowel length .40 cm and intact ICV (20, 24, 25) .
In the PDD group, IBD had the highest rate of weaning off HPN because of the use of biotherapies for the past 15 y. SBS is a condition in which improvements and progressive autonomy are achieved with good outcomes unless impaired by severe complications. CIPOS is a chronic condition with a permanently high level of PN dependency. Our CIPOS subgroup is biased with the most severe forms included in this survey. Congenital enteropathies cause severe and permanent diarrhea. Their prognosis is poor regarding the probability of PN weaning, and those children are candidates for ITx. PNDD had the lowest weaning rate mainly because of the poor prognosis of their underlying disease.
The mortality rate was significantly lower than previously reported by other studies (4, 6, 19, 26) correlated to the degree of liver fibrosis. Different degrees of fibrosis were found in 76% of biopsies in our patients compared with 94% in the Peyret et al. study (21) . These 2 cohorts are not comparable in terms of infection rates, types of lipid emulsions used, and mode of enteral feeding. All children received soybean oil, medium-chain triglycerides, olive oil, and fish oil after 2008, but the follow-up is too short for analysis or conclusion. However, increasing data suggest its efficiency in preventing IFALD (5). Nontransplant surgical procedures reduce the diameter of dilated intestinal loops and may prevent IFALD by improving motility and reducing small intestine bacterial overgrowth (2, 3, 32) . Our experience has been limited to 4 children (data not shown).
We observed peaks of incidence of CRBSIs in 2007-2008 and 2011. The first peak correlated with changes in the CVChandling regimen in our unit. Increased rates of CRBSIs were also reported in intensive care units when mechanical valveneedleless connectors were introduced (33, 34) . The CDC stated that these valves do not increase the incidence of CRBSIs when the access port is wiped with an appropriate antiseptic (35, 36) . In 2013, Hong et al. (37) showed a superior activity of chlorhexidine-alcohol over povidone-iodine (Betadine) (38) . We suspect that the lack of appropriate disinfection explains the first peak of CRBSIs. We have no explanation for the second peak. No statistical difference was found between the PDD and PNDD subgroups.
Coagulase-negative staphylococci were the most frequent cause of CRBSIs. As reported by Gandullia et al. (26) , SA was the major pathogen found in CRBSIs (42%). It was only 10% in Moreau et al. (39) . The overall incidence of SA increased in our unit, leading to catheter replacement and longer antibiotic treatment. Nevertheless, the incidence of CRBSIs decreased after we began using Taurolidine-citrate locks in 2011. Hui-Ping Chu et al. (40) showed a considerable decrease in CRBSIs from 8.6 to 1.1 episodes/1000 d of PN when using Taurolidine-citrate by impeding bacterial adhesion and clot formation. Our results are very promising, as suggested by the drop in CRBSI incidence since 2012 (Figure 2 ). In our experience, children respond well to Actosolv locks (Urokinase) when CVC thrombosis is detected early. Only 6 children in our cohort had their CVC replaced for catheter thrombosis because of Actosolv lock failure. The data on thrombosis were not studied by Colomb et al. (6) . The mechanical valve needleless connectors we have used since 2007 claim to reduce the incidence of thrombosis (34) .
Data on the growth of children on long-term PN are scarce. In 2002, Colomb et al. (41) showed that normal growth was achieved in only 25% of children receiving HPN. The failure to thrive was because of a negative nitrogen balance and insufficient energy. Recent data from Pichler et al. (42, 43) showed better growth in children receiving HPN (SD of 20.8 6 1.3 for weight and 21.8 6 1.5 for height). Children with SBS have a major risk of decreased growth velocity after weaning off of HPN (25, 44) . In this cohort, growth remained normal 6 mo after weaning off of HPN. A longer follow-up is needed to identify the children that will require nutritional support, especially during the onset of puberty (25, 44, 45) . Our experience showed that NPEI from PN 1.5 times the REE allows normal growth in children who were not malnourished (data not shown). Herein the ratio for SBS children was 1.31 6 0.2. During follow-up, this ratio is routinely calculated, and its decrease is an additional criterion that the child is on the path of HPN weaning.
Several articles from the United States deal with "intestinal rehabilitation centers," including early management of IF, especially SBS in both neonatology and surgical wards, with the aim of the earliest PN weaning (46) (47) (48) (49) (50) (51) (52) (53) . Some patients develop severe complications and become candidates for ITx, whereas others fail to be weaned off of PN and are discharged while receiving HPN when suitable. Unfortunately, to our knowledge there is almost no specific report in the literature about the prevalence and results of pediatric HPN programs that makes any comparison with North America possible. One of the reasons is probably related to the differences in the organization and management of IF. The latter are supposed to be shared between pediatric gastroenterology and nutrition teams and home caregiver companies according to the local facilities. In France, patients suffering from IF, including those with SBS, are managed by specialized medical-surgical departments, including pediatric surgeons and pediatric gastroenterologists, nutritionists, and neonatologists. The decision of discharging the child receiving HPN and the follow-up are fully dependent on pediatric gastroenterology and nutrition teams. The French network is organized regionally. Patients are referred to the closest of the 7 reference centers for HPN. Our experience makes us the reference center for a large part of the region. In 2014, of the 262 children who received HPN, 108 (41%) were included in our HPN program. These results reflect our specific management according to the guidelines of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition 2005 and validated protocols. As reported from a European expert panel, an important difference in clinical practice with North America is our limited use of tube feeding (23) . HPN for SBS is mostly based on the combination of cyclical nocturnal PN infusion and oral feeding during the day.
Interestingly, in 1987, our institution became the first European center for pediatric ITx. According to the Intestinal Transplant Registry, only half of the w1700 transplanted pediatric patients are now alive. We do consider that only patients with "nutritional failure" had an increased risk of death while receiving HPN, thus suggesting ITx should be only a life-saving procedure (1, 12, 54) . The latest data reported at the International Small Bowel Transplantation Symposium (Buenos Aires, June 2015) confirmed this result as well as the worldwide reduction in ITx in children because of better IF care, including nontransplant surgery and the use of fish oil-based lipid emulsions (5, 55) .
SBS was the major indication for HPN in our cohort. In our opinion and according to the prognosis after ITx, long-term HPN remains the first-line management for children suffering from IF and confirms continuous improvement, as suggested by shorter HPN duration and decreased mortality. HPN allows normal growth, but close and long-term clinical and biological follow-up after weaning off HPN is mandatory. The probability of weaning is mostly influenced by the underlying disease. CRBSIs decreased after the introduction of TauroLock. IFALD prevalence is low compared with reports in the literature. Finally, early referral to an IF expert center is mandatory for decreasing the rate of complications and discussing ITx in selected cases.
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